03/27/2025

Aromics joins the BME Pre-Market Environment

Aromics, has been incorporated into the Pre-Market Environment (EpM) of Bolsas y Mercados Españoles (BME) with the goal to accelerate growth and access to investment This platform supports innovative companies in their preparation for access to capital markets, offering them visibility with investors and specialised training.
Based in the BCIN building in Badalona, Aromics is committed to a strategy of sustainable growth and openness to private capital, at a key moment for the consolidation of its activity and its international expansion. The company develops innovative compounds that that RNA of cancer-driven genes. Its lead compound, currently advancing into the clinical phase, targets the treatment of malignant mesothelioma, a disease with a high unmet medical need. Aromics is backed by competitive programmes such as the EIC accelerator and more recently the Seal of Excellence program of CDTI, with the support of theNational Recovery, Transformation and Resilience Plan, financed with European Next Generation EU funds, that awards those Spanish R&D compnaies that, like AROMICS, have obtained the Seal of Excellence in the calls of the EIC Accelerator programme. This entire trajectory recognises the scientific and business excellence of the  company as well as its potential to become an international reference in the field of precision oncology.